Ceftriaxone + tazobactam


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult: IV Expressed in terms of ceftriazone/tazobactam: Daily doses of 1000/125 mg in 1-2 divided doses for at least 2 days after the signs and symptoms have resolved. Total daily dose: ≤4 g of ceftriaxone. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, continue for at least 10 days.
Contraindications
Hypersensitivity to cephalosporins and β-lactamase inhibitors.
Special Precautions
History of penicillin allergy; lactation. Consider possibility of pseudomembranous colitis in patients who present with diarrhoea subsequent to the admin of antibacterial agents. Monitor prothrombin time in patients with impaired vit K synthesis or low vit K stores during treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms. Caution in patients with a history of GI disease, especially colitis. Discontinue treatment in patients who develop signs/symptoms suggestive of gallbladder disease. Not to be used in hyperbilirubinemic neonates, especially prematures.
Adverse Reactions
Superinfection; anaphylaxis; diarrhoea; local reactions; blood dyscrasias; rash, fever, pruritus; elevated transaminases and alkaline phosphatase. GI effects; pseudomembranous colitis; hematologic effects; hypersensitivity reactions; CNS disturbances; hypertension; chest pain; edema; moniliasis; rhinitis; dyspnea; hypotension; ileus; syncope; local Inj site reactions; rigors.
Potentially Fatal: Pseudomembranous colitis; nephrotoxicity.
Drug Interactions
Probenecid; aminoglycosides; vecuronium, methotrexate; oral anticoagulants; heparin.
CIMS Class
ATC Classification
J01DD04 - ceftriaxone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
J01CG02 - tazobactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on ceftriaxone + tazobactam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in